Company Logo
Dublin, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The "AAV Vector Market: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
This report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the adeno-associated viral vector market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry.
Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development.
Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral (AAV) vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors based drugs, LUXTURNA and ZOLGENSMA.
A number of adeno-associated viral vector-based therapies are also being evaluated in different clinical trials. In fact, it has been observed that clinical trials evaluating adeno-associated viral vector based therapies have increased at ~30% growth rate over the last few years. Further, it is worth mentioning that over 50 trials are expected to complete in the next three years.
In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors.
In fact, a number of these companies also offer advanced technology platforms, enabling the processing of adeno-associated viral vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective. This is evident from the patents filed for protection of intellectual property related to such technologies.
Story continues
Additionally, multiple partnerships and collaborations have been established between the stakeholders in order to enhance development activity in this industry. Considering the prevalent trends and projected opportunity associated with the overall adeno-associated viral vector / AAV vector domain, we believe that the market is anticipated to witness substantial growth in the foreseen future.
Key Questions Answered
Which adeno-associated viral vector-based therapy candidates are present in the current development pipeline? Which disease indications are targeted by such products?
Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of adeno-associated viral vectors?
Which type of adeno-associated viral vector related technologies are presently offered / being developed by the players in this domain?
Which geographies are the most active in conducting clinical trials related to adeno-associated viral vectors?
Which partnership models are commonly adopted by industry and non-industry stakeholders?
Which companies are likely to partner with adeno-associated viral vector and gene therapy product manufacturers?
What are the different initiatives undertaken by start-ups for the development of adeno-associated viral vectors in the recent past?
Which factors are likely to influence the decision of manufacturing the adeno-associated viral vector in-house or via outsourcing?
How is the current and future market opportunity likely to be distributed across key market segments?
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION3.1. Chapter Overview3.2. Viral and Non-Viral Vectors3.2.1. Viral Vectors3.2.1.1. Adenovirus Vectors3.2.1.2. Adeno-Associated Viral Vectors3.2.1.3. Lentivirus Vectors3.2.1.4. Retrovirus Vectors3.2.1.5. Other Viral Vectors3.2.1.5.1. Alphavirus3.2.1.5.2. Foamy Virus3.2.1.5.3. Simian Virus3.2.1.5.4. Vaccinia Virus3.2.1.5.5. Chimeric Viral Vectors3.2.1.5.6. Herpes Simplex Virus3.2.1.5.7. Sendai Virus3.2.2. Non-Viral Vectors3.2.2.1. Plasmid DNA3.2.2.2. Oligonucleotides3.2.2.3. Liposomes, Lipoplexes, and Polyplexes3.2.2.4. Other Non-Viral Vectors3.3. Adeno-Associated Viral Vectors3.3.1. Structure and Design3.3.2. Adeno-Associated Viral Vector Life Cycle3.3.3. Applications of Adeno-Associated Viral Vectors3.3.3.1. Gene Therapy3.3.3.2. Vaccination3.3.4. Advantages of Adeno-Associated Viral Vectors3.3.5. Challenges Related to Adeno-Associated Viral Vectors3.4. Concluding Remarks
4. ADENO-ASSOCIATED VIRAL VECTOR BASED THERAPY: MARKET LANDSCAPE4.1. Chapter Overview4.2. Adeno-Associated Viral Vector Based Therapy: Overall Market Landscape4.2.1. Analysis by Phase of Development4.2.2. Analysis by Therapeutic Area(s)4.2.3. Analysis by Type of Gene / Molecule Targeted4.2.4. Analysis by Type of Therapy4.2.5. Analysis by Type of Gene Delivery Method Used4.2.6. Analysis by Route of Administration4.3. Adeno-Associated Viral Vector Based Therapy Candidates: Special Designations4.3.1. Analysis by Special Designation(s) Awarded4.4. Adeno-Associated Viral Vector Based Therapy: List of Developers4.4.1. Analysis by Year of Establishment4.4.2. Analysis by Company Size4.4.3. Analysis by Location of Headquarters4.4.4. Adeno-Associated Viral Vector Based Therapy: Leading Developers
5. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURERS: MARKET LANDSCAPE5.1. Chapter Overview5.2. Adeno-Associated Viral Vector Manufacturers: Overall Market Landscape5.2.1. Analysis by Year of Establishment5.2.2. Analysis by Company Size5.2.3. Analysis by Location of Headquarters5.2.4. Analysis by Type of Product(s) Manufactured5.2.5. Analysis by Location of Vector Manufacturing Facilities5.2.6. Analysis by Type of Manufacturer and Company Size5.2.7. Analysis by Scale of Operation5.2.8. Analysis by Location of Headquarters and Scale of Operation5.2.9. Analysis by Application Area(s)
6. ADENO-ASSOCIATED VIRAL VECTOR MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE6.1. Chapter Overview6.2. Adeno-Associated Viral Vector Manufacturing Technologies6.2.1. Analysis by Type of Technology6.2.2. Analysis by Scale of Operation6.2.3. Analysis by Application Area(s)6.2.4. Analysis by Therapeutic Area6.3. Adeno-Associated Viral Vector Technology: List of Developers6.3.1. Analysis by Year of Establishment6.3.2. Analysis by Company Size6.3.3. Analysis by Location of Headquarters6.3.4. Analysis by Company Size and Location of Headquarters6.3.5. Adeno-Associated Viral Vector Technology: Leading Developers
7. DRUG PROFILES7.1. Chapter Overview7.2. Marketed Gene Therapies7.2.1. LUXUTRNA (Spark Therapeutics)7.2.1.1. Company Overview7.2.1.2. Development Timeline7.2.1.3. Mechanism of Action7.2.1.4. Target Indication(s)7.2.1.5. Current Status of Development7.2.1.6. Manufacturing, Dosage and Sales7.2.2. ZOLGENSMA (Novartis)7.2.2.1. Company Overview7.2.2.2. Development Timeline7.2.2.3. Mechanism of Action7.2.2.4. Target Indication(s)7.2.2.5. Current Status of Development7.2.2.6. Manufacturing, Dosage and Sales7.3. Late Stage (Phase II/III and Above) Gene Therapies7.3.1. AGTC 501: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.2. LYS-SAF302: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.3. NFS-01: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.4. RGX-314: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.5. AMT-061: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.6. OAV-101: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.7. PF-06838435: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.8. PF-06939926: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.9. PF-07055480: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.10. SPK-8011: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.11. SRP-9001: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.12. BMN 270: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.13. Lumevoq (GS010): Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results7.3.14. PTC-AADC: Information on Dosage, Mechanism of Action, Clinical Trials and Clinical Trial Results
8. COMPANY PROFILES8.1. Chapter Overview8.2. Abeona Therapeutics8.2.1. Company Overview8.2.2. Financial Information8.2.3. AAV Vector Manufacturing related Capabilities8.2.4. Recent Developments and Future Outlook8.3 Aldevron (Acquired by Danaher)8.3.1. Company Overview8.3.2. Financial Information8.3.3. AAV Vector Manufacturing related Capabilities8.3.4. Recent Developments and Future Outlook8.4 Oxford BioMedica8.4.1. Company Overview8.4.2. Financial Information8.4.3. AAV Vector Manufacturing related Capabilities8.4.4. Recent Developments and Future Outlook8.5 Sanofi (CEPiA, Sanofi Pasteur, Genzyme)8.5.1. Company Overview8.5.2. Financial Information8.5.3. AAV Vector Manufacturing related Capabilities8.5.4. Recent Developments and Future Outlook8.6. WuXi AppTec8.6.1. Company Overview8.6.2. Financial Information8.6.3. AAV Vector Manufacturing related Capabilities8.6.4. Recent Developments and Future Outlook8.7. YPOSKESI8.7.1. Company Overview8.7.2. AAV Vector Manufacturing related Capabilities8.7.3. Recent Developments and Future Outlook
9. COMPANY COMPETITIVENESS ANALYSIS9.1. Chapter Overview9.2. Methodology and Key Parameters9.3. Adeno-Associated Viral Vector Manufacturers: In-house Manufacturers9.3.1. Players based in North America9.3.2. Players based in Europe9.4. Adeno-Associated Viral Vector Manufacturers: Contract Manufacturing Organizations9.4.1. Players based in North America9.4.2. Players based in Europe9.4.3. Players based in Asia-Pacific9.5. Adeno-Associated Viral Vector Manufacturers: Both In-House and Contract Manufacturing Organizations9.5.1. Players based in North America9.5.2. Players based in Europe9.5.3. Players based in Asia-Pacific
10. TECHNOLOGY COMPETITIVENESS ANALYSIS10.1. Chapter Overview10.2. Methodology and Key Parameters10.3. Adeno-Associated Viral Vector Technology Platforms10.3.1. Adeno-Associated Viral Vector Technology Platforms Developed by Companies10.3.2. Adeno-Associated Viral Vector Technology Platforms Developed by Companies based in Europe and Asia-Pacific
11. CLINICAL TRIAL ANALYSIS11.1. Chapter Overview11.2. Scope and Methodology11.3. Adeno-Associated Viral Vector Based Therapies: Clinical Trial Analysis
12. PARTNERSHIPS AND COLLABORATIONS12.1. Chapter Overview12.2. Partnership Models12.3. Adeno-Associated Viral Vector based Therapies: List of Partnerships and Collaborations12.4. Adeno-Associated Viral Vector Manufacturers: List of Partnerships and Collaborations
13. STRATEGIC PARTNER ANALYSIS
14. PATENT ANALYSIS
15. START-UP HEALTH INDEXING
16. OUTSOURCING: GO / NO-GO FRAMEWORK
17. MARKET SIZING AND OPPORTUNITY ANALYSIS
18. CONCLUDING REMARKS
19. EXECUTIVE INSIGHTS
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/6ev168
Go here to read the rest:
- About the Gene Therapy Review - November 8th, 2009 [November 8th, 2009]
- Contribute an Article - November 8th, 2009 [November 8th, 2009]
- EBSCO Publishing Deal - November 8th, 2009 [November 8th, 2009]
- Advertising Opportunities - November 8th, 2009 [November 8th, 2009]
- Instructions for Authors - November 8th, 2009 [November 8th, 2009]
- Isis Collaboration With Ortho-McNeil Inc for Metabolic Diseases - November 8th, 2009 [November 8th, 2009]
- Dystrophin Gene Transfer safe in Duchenne muscular dystrophy - November 8th, 2009 [November 8th, 2009]
- Researchers Identify Gene for Rare Form of Spinal Muscular Atrophy - November 8th, 2009 [November 8th, 2009]
- Fatal brain cancer tamed by New gene therapy - November 8th, 2009 [November 8th, 2009]
- Gene therapy effective in fighting obesity in mice - November 8th, 2009 [November 8th, 2009]
- Genzyme gene therapy for people with peripheral artery disease failed in a clinical trial to help them regain some mobility - November 8th, 2009 [November 8th, 2009]
- Gene Therapy May Stall Inherited Emphysema - December 31st, 2009 [December 31st, 2009]
- Gene Therapy and Stem Cells Save Limb - December 31st, 2009 [December 31st, 2009]
- TNVitamins.com – $10 Off Of $50 order - May 7th, 2011 [May 7th, 2011]
- 15% Off Any PetAlive Order - May 7th, 2011 [May 7th, 2011]
- At PetAlive – $10 off order of $50 or more - May 7th, 2011 [May 7th, 2011]
- Native Remedies coupon – 5% Off Any Order - May 7th, 2011 [May 7th, 2011]
- Native Remedies – Save $5 coupon - May 7th, 2011 [May 7th, 2011]
- Welcome to the Gene Therapy Review - May 15th, 2011 [May 15th, 2011]
- Editorial Board - May 15th, 2011 [May 15th, 2011]
- Gene Therapy Job Board - May 15th, 2011 [May 15th, 2011]
- Corporate Membership - May 22nd, 2011 [May 22nd, 2011]
- Native Remedies coupon – 25% Off Any Order - May 29th, 2011 [May 29th, 2011]
- What is Gene Therapy? - June 19th, 2011 [June 19th, 2011]
- Research and Markets: Recent Advances in Cancer Research and Therapy - Increased Research on one of the Major Causes ... - April 25th, 2012 [April 25th, 2012]
- Gene Therapy part 2 - Video - April 30th, 2012 [April 30th, 2012]
- Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- CBS This Morning - Gene therapy reverses Parkinson's symptoms: study - Video - April 30th, 2012 [April 30th, 2012]
- Engineering adenoviruses for gene therapy - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy (The General Explains) - Video - April 30th, 2012 [April 30th, 2012]
- What is Gene Therapy - Animation - Video - April 30th, 2012 [April 30th, 2012]
- Microbiology Gene Therapy - Video - April 30th, 2012 [April 30th, 2012]
- Gene Therapy in Detail - Video - April 30th, 2012 [April 30th, 2012]
- Breakthrough in Haemophilia treatment - Video - April 30th, 2012 [April 30th, 2012]
- Virology Seminar - Gene Therapy - April 30th, 2012 [April 30th, 2012]
- Gene Therapy Video - Video - April 30th, 2012 [April 30th, 2012]
- Study: Gene Therapy for HIV Safe, But Effectiveness Still Unclear - May 4th, 2012 [May 4th, 2012]
- Gene Therapy Safe in Decade-Long HIV Study That May Widen Use - May 4th, 2012 [May 4th, 2012]
- Gene therapy for HIV safe, but effectiveness still unclear - May 4th, 2012 [May 4th, 2012]
- A Step Forward For Gene Therapy To Treat HIV - May 4th, 2012 [May 4th, 2012]
- A Media Event on Clinical Developments in Gene and Cell Therapy - May 4th, 2012 [May 4th, 2012]
- Families of SMA Awards New Funding to Advance a CNS Delivered Gene Therapy for Spinal Muscular Atrophy - May 4th, 2012 [May 4th, 2012]
- AIDS gene therapy safe -- is it a "cure"? - May 4th, 2012 [May 4th, 2012]
- Generational Achievements in Gene and Cell Therapy Honored at ASGCT 15th Annual Meeting - May 5th, 2012 [May 5th, 2012]
- Lewis speaks on gene therapy at Lexington Community Education event - May 7th, 2012 [May 7th, 2012]
- Penn researchers report a gene-therapy success - May 10th, 2012 [May 10th, 2012]
- Gene therapy for hearing loss: Potential and limitations - May 13th, 2012 [May 13th, 2012]
- Gene therapy extends mouse lifespan by 24 pc - May 16th, 2012 [May 16th, 2012]
- Gene therapy dramatically extends mouse lifespan - May 16th, 2012 [May 16th, 2012]
- Gene therapy may extend life: Study - May 16th, 2012 [May 16th, 2012]
- First gene therapy successful against aging-associated decline: Mouse lifespan extended up to 24% with a single ... - May 16th, 2012 [May 16th, 2012]
- Gene Therapy Extends Mouse Lifespan - May 16th, 2012 [May 16th, 2012]
- Gene Therapy for Brain Disease - May 17th, 2012 [May 17th, 2012]
- Children with rare, incurable brain disease improve after gene therapy - May 17th, 2012 [May 17th, 2012]
- FIRST Anti-Aging Gene Therapy (Brainstorm Ep72) - Video - May 23rd, 2012 [May 23rd, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency - May 25th, 2012 [May 25th, 2012]
- RetroSense Therapeutics Completes pre-IND Meeting for RST-001 - May 25th, 2012 [May 25th, 2012]
- Gene therapy can correct forms of severe combined immunodeficiency, study suggests - May 26th, 2012 [May 26th, 2012]
- Alliance for Cancer Gene Therapy celebrates 10 years - May 29th, 2012 [May 29th, 2012]
- Research on gene therapy by Prasad Eye - June 1st, 2012 [June 1st, 2012]
- Baxter Announces Collaboration with Chatham Therapeutics for Factor IX Hemophilia B Gene Therapy Treatment - June 5th, 2012 [June 5th, 2012]
- Transgenomic Launches Breakthrough Blood-Based Cancer Gene Testing Technology at 2012 ASCO Annual Meeting - June 5th, 2012 [June 5th, 2012]
- Baxter Inks Deal with Chatham - June 6th, 2012 [June 6th, 2012]
- PIK3CA Gene Patent for Predicting Response to Targeted Therapy Issued – Exclusively Licensed to Transgenomic - June 11th, 2012 [June 11th, 2012]
- SalutarisMD Announces Positive Case Report of a New Investigational Wet AMD Therapy at ARVO - June 15th, 2012 [June 15th, 2012]
- Research and Markets: Gene Therapy - Global Strategic Business Report - 2012 - June 15th, 2012 [June 15th, 2012]
- New York Law Firm’s MesotheliomaHelp.net Site Publishes Interview with Gene Therapy Author - June 17th, 2012 [June 17th, 2012]
- uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy - June 19th, 2012 [June 19th, 2012]
- Anti-cocaine vaccine described in Human Gene Therapy Journal - June 19th, 2012 [June 19th, 2012]
- bluebird bio Receives U.S. and European Orphan Drug Designation for Novel Gene Therapy to Treat Adrenoleukodystrophy - June 19th, 2012 [June 19th, 2012]
- Close to a cure: Greater Hartford takes on rare Jewish genetic disease - June 19th, 2012 [June 19th, 2012]
- Gene Therapy Helps Treat Children with Rare Brain Disorder - June 20th, 2012 [June 20th, 2012]
- Gold nanoparticles capable of 'unzipping' DNA - June 21st, 2012 [June 21st, 2012]
- ‘Gene-silencing’ drug can halt and reverse deadly brain disorder - June 21st, 2012 [June 21st, 2012]
- uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson's Disease - June 22nd, 2012 [June 22nd, 2012]
- Gene-silencing method offers possible therapy for Huntington's disease - June 22nd, 2012 [June 22nd, 2012]
- Gene mutations cause massive brain asymmetry - June 24th, 2012 [June 24th, 2012]
- Research and Markets: Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features ... - June 25th, 2012 [June 25th, 2012]
- Stress Blocks Gene That Guards Brain Against Depression - June 26th, 2012 [June 26th, 2012]
- Targeted gene therapy enhances treatment for Pompe disease - June 26th, 2012 [June 26th, 2012]